Clinical Trial

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

Study acronym: STRIVE II
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-24.
Trial Details
NCT Number NCT07674745
Lead Sponsor University of Alabama at Birmingham
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 52 participants
Start Date 2026-10-01
Primary Completion 2030-09-30 (estimated)
Study Completion 2031-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01